摘要
在本文中,我们希望带您进入分子医学世界,因为在过去几十年中,随着基因组学的发展,分子医学已经发展起来。这些发现促进了预后参数的发展和治疗策略的发展。在本手稿中,我们将以造血系统疾病为例来说明这一进展,因为它们不仅与它们的发生频率有关,而且与明显的诊断和治疗进展有关。对基本病理生理学的日益了解源自例如Rudolf Virchow(1821-1902)所描述的细胞病理学。血液恶性肿瘤和实体瘤疾病特定基因组变化的鉴定为我们提供了非常灵敏的工具,用于诊断和预测预后。因此,它为个性化或个性化治疗铺平了道路。特别地,使用下一代测序(NGS)的人类基因组测序技术的快速发展为这一进展做出了贡献。最近,人工智能为我们提供了分析基因组变化,疾病进程以及其他尚不重要的因素的复杂相互作用的工具。通过所有这些无可争议的改进,我们不应忽略个性化治疗的整体治疗要求,即适合个人的治疗。在这种情况下,主治医师应处理相关的合并症,患者的社会心理嵌入及其对治疗的渴望。
关键词: 骨髓恶性肿瘤,下一代测序,诊断,靶向治疗,预后,人工智能,同种异体干细胞移植。
图形摘要
Current Drug Targets
Title:Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Volume: 22 Issue: 2
关键词: 骨髓恶性肿瘤,下一代测序,诊断,靶向治疗,预后,人工智能,同种异体干细胞移植。
摘要: With this article, we would like to take the reader on a journey into the world of molecular medicine as it has evolved over the past decades, enabled by advances in genomics. These findings advanced both the development of prognostic parameters and the evolvement of therapy strategies. In this manuscript, we will present haematopoietic diseases as a prime example of this progress because they are relevant not only for their frequency but also for the evident diagnostic and therapeutic progress. The growing understanding of the underlying pathophysiology originates from the cellular pathology as it was described by, e.g., Rudolf Virchow (1821-1902). The identification of specific genomic changes in haematological malignancies and solid tumour diseases provided us with very sensitive tools for diagnostics and prediction of prognosis. Thus, it paved the way for individualized or personalized therapy. In particular, the rapid development of sequencing techniques for the human genome using Next Generation Sequencing (NGS) has contributed to this progress. Recently, artificial intelligence provided us with the tools to analyze the complex interactions of genomic alterations, course of the disease, and further factors of as yet unknown significance. With all these indisputable improvements, we should not neglect the holistic treatment mandate of personalized therapy, i.e., therapy appropriate to the individual. In this context, the treating physician should address relevant co-morbidities, the psychosocial embedding of the patient and his desire for treatment.
Export Options
About this article
Cite this article as:
Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine, Current Drug Targets 2021; 22 (2) . https://dx.doi.org/10.2174/1389450121666201001122816
DOI https://dx.doi.org/10.2174/1389450121666201001122816 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer
Current Pharmaceutical Design Comprehensive Comparison of Trace Metal Concentrations in Cancerous and Non-Cancerous Human Tissues
Current Medicinal Chemistry Functionalized Silver Nanoparticles for Sensing, Molecular Imaging and Therapeutic Applications
Current Nanomedicine Induction of GST and Related Events by Dietary Phytochemicals: Sources, Chemistry, and Possible Contribution to Chemoprevention
Current Topics in Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Cisplatin Resistance and Transcription Factors
Current Medicinal Chemistry - Anti-Cancer Agents Leaf Extract of <i>Nerium oleander</i> L. Inhibits Cell Proliferation, Migration and Arrest of Cell Cycle at G2/M Phase in HeLa Cervical Cancer Cell
Anti-Cancer Agents in Medicinal Chemistry Systematic Patent Review of Nanoparticles in Drug Delivery and Cancer Therapy in the Last Decade
Recent Advances in Drug Delivery and Formulation Discovery of Cationic Polymers for Non-Viral Gene Delivery Using Combinatorial Approaches
Combinatorial Chemistry & High Throughput Screening Role of Flavonoids in the Prevention of Gynecological Cancers: Epidemiological Clues
Current Women`s Health Reviews MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Magnetic Resonance Imaging of the Cervix, and its Relevance to the Revised International Federation of Gynecology and Obstetrics (FIGO) Staging
Current Medical Imaging Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Genetic Markers of Osteoarthritis
Current Rheumatology Reviews Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Human Papillomavirus E7 Oncoprotein Promotes Proliferation and Migration through the Transcription Factor E2F1 in Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry